Controversies in the Treatment of Follicular Lymphoma
Open Access
- 10 January 2020
- journal article
- research article
- Published by Wiley in HemaSphere
- Vol. 4 (1), e317
- https://doi.org/10.1097/hs9.0000000000000317
Abstract
The overall prognosis of patients with follicular lymphoma has substantially improved over the last decades with a 10-year overall survival of around 80% for the majority of patients. However, for most patients follicular lymphoma it is still a relapsing and remitting disease. Furthermore, certain subsets of patients still have much shorter survival. Currently, there is no established standard how to treat high-risk follicular lymphoma. With advances in the understanding of the biology and pathogenesis of B cell malignancies, a plethora of new compounds have been investigated in FL. These compounds have the potential to increase efficacy if added to current regimens or even replace them. The implementation of these compounds in treatment algorithms is another unsolved issue. This overview highlights major controversies in the treatment of follicular lymphoma and discusses the most recent and relevant clinical trials.Funding Information
- Bristol-Myers Squibb
- Merck
- Seattle Genetics
- Pfizer
- Gilead Sciences
- Sanofi
- Spectrum Pharmaceuticals
- Amgen
This publication has 75 references indexed in Scilit:
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN StudyJournal of Clinical Oncology, 2013
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experienceBlood, 2013
- Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working PartyHaematologica, 2013
- Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare StudyJournal of Clinical Oncology, 2012
- Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter studyBlood, 2012
- Temsirolimus Has Activity in Non–Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II ConsortiumJournal of Clinical Oncology, 2010
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicityBlood, 2010
- Follicular Lymphoma in the United States: First Report of the National LymphoCare StudyJournal of Clinical Oncology, 2009
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003